Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / COM
-
Number of holders
-
160
-
Total 13F shares, excl. options
-
18,504,038
-
Shares change
-
-231,062
-
Total reported value, excl. options
-
$1,081,008,395
-
Value change
-
-$13,098,519
-
Put/Call ratio
-
70.3%
-
Number of buys
-
85
-
Number of sells
-
-72
-
Price
-
$58.42
Significant Holders of INTERCEPT PHARMACEUTICALS IN - COM (ICPT) as of Q4 2017
218 filings reported holding ICPT - INTERCEPT PHARMACEUTICALS IN - COM as of Q4 2017.
INTERCEPT PHARMACEUTICALS IN - COM (ICPT) has 160 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 18,504,038 shares
.
Largest 10 shareholders include FMR LLC (3,765,300 shares), JPMORGAN CHASE & CO (1,932,734 shares), Vanguard Group Inc (1,405,731 shares), STATE STREET CORP (1,251,401 shares), BlackRock Inc. (1,193,962 shares), Capital World Investors (1,163,759 shares), Senvest Management, LLC (970,926 shares), FIRST TRUST ADVISORS LP (605,454 shares), BB BIOTECH AG (485,719 shares), and MORGAN STANLEY (424,019 shares).
This table shows the top 160 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.